Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04079166
Title SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Scancell Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.